# Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine

> **NCT05329038** · PHASE4 · UNKNOWN · sponsor: **Sinovac Life Sciences Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Inactivated COVID-19 Vaccine

## Key facts

- **NCT ID:** NCT05329038
- **Lead sponsor:** Sinovac Life Sciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-19
- **Primary completion:** 2022-06-19
- **Final completion:** 2024-02-20
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05329038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05329038, "Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05329038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*